|
Originally published In Press as doi:10.1074/jbc.M108640200 on January 23, 2002
J. Biol. Chem., Vol. 277, Issue 15, 12946-12952, April 12, 2002
Hormone-sensitive Lipase Deficiency in Mice Changes the Plasma
Lipid Profile by Affecting the Tissue-specific Expression Pattern of
Lipoprotein Lipase in Adipose Tissue and Muscle*
Guenter
Haemmerle ,
Robert
Zimmermann ,
Juliane G.
Strauss ,
Dagmar
Kratky ,
Monika
Riederer ,
Gabriele
Knipping§, and
Rudolf
Zechner ¶
From the Institute of Molecular Biology,
Biochemistry, and Microbiology and the § Institute of
Medical Biochemistry and Molecular Biology, University of Graz,
Graz A-8010, Austria
Received for publication, September 7, 2001, and in revised form, December 23, 2001
 |
ABSTRACT |
Hormone-sensitive lipase
(HSL) is believed to play an important role in the mobilization of
fatty acids from triglycerides (TG), diglycerides, and cholesteryl
esters in various tissues. Because HSL-mediated lipolysis of TG in
adipose tissue (AT) directly feeds non-esterified fatty acids (NEFA)
into the vascular system, the enzyme is expected to affect many
metabolic processes including the metabolism of plasma lipids and
lipoproteins. In the present study we examined these metabolic changes
in induced mutant mouse lines that lack HSL expression (HSL-ko mice).
During fasting, when HSL is normally strongly induced in AT, HSL-ko
animals exhibited markedly decreased plasma concentrations of NEFA
( 40%) and TG ( 63%), whereas total cholesterol and HDL cholesterol
levels were increased (+34%). Except for the increased HDL cholesterol
concentrations, these differences were not observed in fed animals,
in which HSL activity is generally low. Decreased plasma TG
levels in fasted HSL-ko mice were mainly caused by decreased hepatic
very low density lipid lipoprotein (VLDL) synthesis as a result of
decreased NEFA transport from the periphery to the liver. Reduced NEFA
transport was also indicated by a depletion of hepatic TG stores
( 90%) and strongly decreased ketone body concentrations in plasma
( 80%). Decreased plasma NEFA and TG levels in fasted HSL-ko mice
were associated with increased fractional catabolic rates of VLDL-TG and an induction of the tissue-specific lipoprotein lipase (LPL) activity in cardiac muscle, skeletal muscle, and white AT. In brown AT,
LPL activity was decreased. Both increased VLDL fractional catabolic
rates and increased LPL activity in muscle were unable to provide the
heart with sufficient NEFA, which led to decreased tissue TG levels in
cardiac muscle. Our results demonstrate that HSL deficiency markedly
affects the metabolism of TG-rich lipoproteins by the coordinate
down-regulation of VLDL synthesis and up-regulation of LPL in muscle
and white adipose tissue. These changes result in an
"anti-atherogenic" lipoprotein profile.
 |
INTRODUCTION |
In mammals, white adipose tissue (WAT)1 is the most
important storage organ of TG. The
mobilization of TG during fasting or periods of increased energy
demand, and the release of non-esterified fatty acids (NEFA) is an
essential process that supplies non-adipose organs with substrates for
energy conversion (1, 2). NEFA absorbed by skeletal and cardiac muscle
are predominantly used for oxidation and energy production. In the
liver, NEFA are also used for oxidation but, in addition, are utilized
for several other metabolic processes. NEFA can be stored as hepatic TG
droplets, used for the synthesis of ketone bodies, or incorporated into VLDL (3, 4). Once formed, VLDL particles are secreted from the
liver into the vascular system where they are lipolyzed by endothelial
cell associated lipoprotein lipase (LPL) (5, 6). This process supplies
peripheral tissues such as AT with NEFA, thereby closing an
inter-tissue cycle of fatty acid transport.
An important enzyme for the mobilization of TG and NEFA production in
AT is hormone-sensitive lipase (HSL). This multifunctional neutral
lipase hydrolyzes TG, diglycerides, cholesteryl esters, retinyl esters
(7-10), and possibly other, yet unidentified, substrates. Although the
highest levels of expression are found in WAT and brown adipose tissue
(BAT), the enzyme is also found in many other tissues including muscle
(2), macrophages (11), testis (12), and pancreas (13). In the
postprandial state, HSL activity accounts for most of the detectable
lipolysis in human WAT and thus determines whole-body lipid fuel
availability (14, 15). In WAT, the enzyme activity is activated by
hormones such as catecholamines. Stimulation of adenylyl cyclase
activity (16-20) results in a rise in the intracellular cAMP levels
that activate protein kinase A (21). Protein kinase A-mediated
phosphorylation of HSL promotes the formation of a stable complex
between HSL and lipotransin (22), which translocates the enzyme from
the cytosol to the lipid droplet. In response to hormone signals,
lipotransin-mediated ATP hydrolysis causes HSL to dissociate and thus
gain access to the lipid surface. Insulin, the major antilipolytic
hormone, inhibits HSL through phosphodiesterase-3-dependent cAMP degradation and interference with the lipotransin-mediated enzyme translocation.
Recently, the rate-limiting function of HSL in the catabolism of WAT TG
was challenged by studies in HSL knock-out (ko) mice (23). HSL
deficiency was compatible with normal body weight and fat mass,
suggesting that at least one alternative lipase must exist in WAT to
compensate for the hydrolysis of TG in the absence of HSL. Nonetheless,
HSL-ko mice exhibited increased mass of BAT and marked changes in the
lipid composition of WAT, BAT, and other tissues of the body (23, 24).
Additionally, in vitro lipolysis studies with isolated WAT
revealed decreased NEFA and glycerol release when HSL was absent, thus
arguing for a crucial role of HSL in the catabolism of TG and
diglycerides and the subsequent release of NEFA (24). As a result, the
plasma levels of NEFA are decreased in fasting HSL-deficient mice
(23).
Depending on the nutritional condition, plasma NEFA strongly affect
lipid synthesis and utilization in hepatic and peripheral tissues (25).
Accordingly, decreased NEFA release in HSL-ko mice is expected to
result in decreased hepatic VLDL synthesis and other metabolic changes.
To test this hypothesis, we studied the role of HSL deficiency on the
metabolism of plasma lipids and lipoproteins in HSL-ko mice. We
demonstrate that decreased plasma NEFA levels in HSL-deficient mice are
associated with decreased hepatic VLDL synthesis, decreased
ketogenesis, and the depletion of TG stores in the liver. Additionally,
the catabolism of plasma VLDL is increased because of the coordinate
up-regulation of the tissue-specific LPL activity in muscle and WAT,
which results in drastically reduced plasma TG levels and increased HDL
cholesterol concentrations in fed and fasted HSL-ko mice.
 |
EXPERIMENTAL PROCEDURES |
Animals--
HSL-ko mice were generated by targeted homologous
recombination as previously described (24). For breeding experiments
mice heterozygous for the deleted HSL allele were used to generate homozygous HSL-ko mice. Mice were maintained on a regular light-dark cycle (14 h light, 10 h dark) and kept on a standard laboratory chow diet (4.5% w/w fat). Genotyping of HSL-ko mice was performed by a
single-step PCR using three primers as described previously (24).
Blood Parameters--
Samples were drawn by retro-orbital
puncture from animals in the fed and fasted state. Blood was obtained
from mice in the mornings after they had normal access to food (fed
samples) and from mice after they were fasted for a period of 16 h. Total cholesterol (TC), HDL cholesterol, TG, and NEFA were
determined using commercial kits (Roche Molecular Biochemicals;
Sigma; and Wako Chemicals, Neuss, Germany). Ketone bodies
( -hydroxybutyrate) were determined using a commercial kit from Sigma.
Lipoprotein Analysis--
Plasma samples of five fasted HSL-ko
and five control mice were pooled. TG, TC, and PL contents were
quantitated enzymatically using commercial kits (Sigma; bioMerieux
Inc., Durham, NC). Lipoproteins were isolated by fast protein liquid
chromatography (FPLC) using a Pharmacia FPLC system and a Superose 6 column (Amersham Biosciences). Plasma samples (250 µl) were applied
to FPLC analysis and eluted with 10 mM Tris-HCl, 1 mM EDTA, 154 mM NaCl, and 0.02%
NaN3 (pH 7.4). Fractions of 0.5 ml each were collected and
enzymatically assayed for TG, TC, and PL contents.
Cryosections and TG Determination in the Liver and Cardiac
Muscle--
After perfusion with 0.9% NaCl for removal of blood
lipids, organs from fed and fasted mice were instantly frozen in liquid nitrogen. Sections (5 µm) were prepared at 20 °C from tissues embedded in OCT compound (Sakura) and transferred to commercial glass slides. To visualize neutral lipids, the cryosections were stained with Oil Red O (Sigma). Nuclei were stained with
hemalaun (Sigma-Aldrich) following a standard protocol (26). The
stained sections were analyzed by light microscopy and photographed (3 CCD color video camera, Sony, Power HAD).
The tissue TG content was determined from blood free tissues. After
anesthesia, mice were perfused with a 0.9% NaCl solution. Livers and
hearts were excised, weighed, and frozen. Total lipids were extracted
from organs by the method of Folch (27). Lipid extracts were incubated
in a buffer containing 4 units/ml Candida rugosa
lipase (Sigma), 50 mM Tris-HCl pH 7.4, 5% bovine serum albumin for 3 h at 37 °C to achieve complete TG hydrolysis.
Subsequently the released glycerol was quantitated with a commercially
available TG-kit (GPO-Trinder) obtained from Sigma.
In Vivo Synthesis of VLDL--
Hepatic TG synthesis rates were
determined after blocking the lipolytic degradation of TG-rich
lipoproteins with Triton WR1339 (28) according to a standard protocol
(29). Anesthetized fasted mice were injected intravenously with 500 mg
of Triton WR1339 (Sigma)/kg of body weight as a 15 g/dl solution in
0.9% NaCl. Blood samples were drawn before injection of Triton WR1339
and 1, 2, 3, and 4 h after injection. TG values were determined
from plasma using an enzymatic kit (GPO-Trinder, Sigma).
In Vivo Clearance of Labeled VLDL--
For clearance studies,
VLDL was labeled in vivo in control mice. Fasted mice were
injected intravenously with [1,2-3H]palmitate (200 µCi) and bled 35 min after the injection. Plasma samples were
ultracentrifuged to obtain the VLDL fraction. TLC on silica gel G
plates using a hexane-diethylether-acetic acid solution (70:29:1) as
the solvent revealed that 98% of the radioactivity was in the TG
fraction. Anesthetized mice were injected intravenously with 400,000 cpm of radiolabeled VLDL, and the disappearance of radioactivity was
determined from plasma samples drawn 0.5, 1, 2, 3, 5, 10, 15, and 30 min after the injection. Data were analyzed for individual animals
using a two-pool model, and the fractional catabolic rate (FCR) as well
as the absolute catabolic rate (ACR) were calculated (30, 31).
Assay of Tissue Lipoprotein Lipase Activity--
LPL activity in
tissue was determined in 3-month-old female mice. Enzyme activities
were determined in both the fed and the fasted state. The tissues were
surgically removed from the animals and put into ice-cold tubes
containing 1 ml of Dulbecco's modified Eagle's medium with 2% bovine
serum albumin and 2 units/ml heparin. After the tissue was minced with
scissors, it was incubated in medium for 1 h at 37 °C. Enzyme
activities of LPL were assayed as described earlier (32).
Analysis of LPL mRNA in WAT, BAT, and Cardiac
Muscle--
Tissues from fasted mice were surgically removed, weighed,
and subsequently frozen in liquid nitrogen. Wet tissues were
homogenized in 5 ml TRI reagent (Molecular Research Center,
Inc., Karlsruhe, Germany), and total tissue RNA was prepared as
described previously (33). For Northern blotting analysis, 10 µg of
total RNA were separated by 1% formaldehyde-agarose gel
electrophoresis and blotted overnight onto nylon membranes (Hybond N+,
Amersham Biosciences). Subsequently, the RNA was cross-linked to the
membrane by ultraviolet irradiation. Blots were prehybridized for
4 h at 65 °C in a buffer containing 0.15 M sodium
phosphate (pH 7.2), 1 mM EDTA, 7% SDS, and 1% bovine
serum albumin. Membranes were hybridized in the same buffer at 65 °C
overnight with a specific mouse LPL cDNA probe as previously
described (34). After hybridization, the blots were washed, and
specific hybridization was visualized by a 3-h exposure to a
phosphorimaging screen (Apbiotech, Freiburg, Germany). Signal
intensities were quantified in relation to the 28 S rRNA corresponding
band by ImageQuant 5.1 Software (Apbiotech).
Statistical Analysis--
Results are given as the mean ± S.D. Statistical significance was tested using two-tailed Student's
t test.
 |
RESULTS |
Plasma Lipid and Lipoprotein Analysis--
The consequences of HSL
deficiency with regard to plasma lipid levels were investigated
in the fed and the fasted states (Table I). In the fed state, plasma TG and NEFA
concentrations were not significantly altered in HSL-ko mice compared
with controls. In the fasted state, plasma TG and NEFA levels of HSL-ko
mice were markedly decreased by 63 and 39%, respectively. Independent of the dietary status, plasma cholesterol levels were increased in
HSL-ko mice by 30-40%. This increase was mainly because of increased
HDL cholesterol levels. Essentially identical results were obtained
from three independent experiments (data not shown).
View this table:
[in this window]
[in a new window]
|
Table I
Plasma TG, FFA, total cholesterol, and HDL cholesterol
concentrations
Data represent means ± S.D. Blood was drawn from 14-16-week-old
female mice in the fed or fasted state. n1 = number of animals used for measurements.
|
|
To investigate the lipid distribution among lipoprotein subclasses,
plasma samples of fasted HSL-ko animals and controls were subjected to
FPLC analysis (Fig. 1). TG measurements
in FLPC subfractions revealed a 41% reduction of the VLDL-TG fraction
of HSL-ko mice. In contrast, HDL cholesterol was increased by 48% in
HSL-ko animals compared with controls. LDL-cholesterol levels were
barely detectable in both HSL-ko and wt mice.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 1.
Lipoprotein profile. Lipoprotein profile
of plasma pools from five fasted HSL-wt and 5 HSL-ko mice at the age of
14 weeks. Plasma lipoproteins were separated using a Pharmacia FPLC
system with a Superose 6 column. FPLC fractions were collected, and TG,
TC, and PL concentrations were measured in each fraction
enzymatically.
|
|
Decreased Hepatic Fatty Acid Utilization for VLDL Synthesis, TG
Storage, and Ketogenesis in HSL-ko Mice--
To study the underlying
cause of the reduced TG levels in HSL-ko mice, we investigated liver TG
synthesis in fasted HSL-ko animals and control mice. Hepatic TG
synthesis was determined in vivo after blocking the
lipolytic catabolism of TG-rich lipoproteins with Triton WR1339. The
injection of Triton WR1339 resulted in a linear increase in plasma TG
concentrations between 1 and 4 h after injection (Fig.
2A). Linear regression
analysis of the increase in plasma TG concentrations between 1 and
4 h after injection (Fig. 2B) revealed that HSL-ko mice
produced only 41% of the TG mass found in control mice, suggesting
that the impaired NEFA transport to the liver during fasting markedly
reduces hepatic VLDL synthesis.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 2.
Triglyceride production in Triton
WR1339-treated mice. Anesthetized fasted mice were injected
intravenously with 500 mg of Triton WR1339/kg of body weight as a 15 g/dl solution in 0.9% NaCl. Plasma TG were determined before and after
Triton WR1339 injection at a time course of 4 h (A). TG
synthesis rate was calculated by linear regression from the increase in
plasma TG between 1 and 4 h after injection (B). Data
are shown as the mean ± S.D. of 6 wt- and 6 ko mice. *,
p < 0.05; **, p < 0.01; ***,
p < 0.001.
|
|
To analyze whether decreased plasma NEFA concentrations
also affected the hepatic TG content, cryosections of liver tissues were performed and stained for neutral lipids with Oil Red. As shown in
Fig. 3A neutral lipids were
barely detectable in the liver of fasted HSL-ko mice, whereas control
animals exhibited clearly visible stained lipid droplets. Biochemical
determination of intracellular TG concentrations revealed a drastic
92% reduction of the liver TG content in HSL-ko mice compared with
control mice (Fig. 3B). In the fed state, liver TG contents
were not altered in HSL-ko animals compared with controls.

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 3.
Liver cryosections and liver TG
contents. A, liver cryosections were performed
with pieces of livers from mice fasted overnight. Before taking livers,
we perfused the mice with 0.9% NaCl to remove any blood lipids. For
visualizing neutral lipids, 5 µm tissue sections were stained with
Oil Red. B, liver TG contents of mice in the fed and
fasted (16 h) states. Tissues were homogenized, and tissue lipids were
extracted by the method of Folch (27). TG contents were
determined enzymatically. Values represent means ± S.D. **,
p < 0.01.
|
|
HSL deficiency also resulted in a 69 and 78% decrease in
plasma ketone body ( -hydroxybutyrate) concentrations (Fig.
4) in the fed and fasted state,
respectively, again arguing for reduced utilization of NEFA for hepatic
ketogenesis.

View larger version (9K):
[in this window]
[in a new window]
|
Fig. 4.
Plasma ketone bodies. Ketone bodies
( -hydroxybutyrate) were determined from 16-week-old female mice
(n = 6) in the fed and fasted states. Values represent
means ± S.D. *, p < 0.05; ***, p < 0.001.
|
|
Increased VLDL Clearance in HSL-ko Mice--
To study the removal
of VLDL particles from the circulation, fasted HSL-ko mice and controls
were injected intravenously with 400,000 cpm of in vivo
radiolabeled VLDL TG. As shown in Fig. 5,
the VLDL half-time in the circulation was decreased ~2-fold in HSL-ko
mice compared with controls (7.8 ± 2.0 versus 4.0 ± 1.1 min in controls and HSL-ko mice, respectively). The fractional catabolic rates for VLDL-TG were calculated from the plasma
decay curves, assuming a two-pool model, by the method of Mathews (30, 31). The mean FCR were 7.2 ± 1.5 and 12.7 ± 2.3 pools/h
(Fig. 5) in HSL-wt and HSL-ko mice, respectively. Despite the 76%
increase of the FCR in HSL-ko mice, the absolute catabolic rate
as a product of the FCR × pool size was decreased by 31% because
of the drastically decreased plasma TG levels in fasted HSL-ko mice.
Considering that under steady state conditions the ACR reflects the
production rate (30, 31), these data support the finding of decreased VLDL synthesis in HSL-deficient mice.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 5.
VLDL turnover study. VLDL was labeled
in vivo with [3H]palmitate and injected
intravenously into ko- and wt mice, which were fasted for a period of
16 h. At the indicated time points, blood samples were drawn, and
the remaining radioactivity in the plasma was determined. The
radioactivity obtained after 30 s was set at 100% for each curve.
The FCR for VLDL-TG were calculated from the plasma decay curves,
assuming a two-pool model by the method of Mathews (30, 31). The ACR
was calculated as the product of the FCR × pool size. Data are
shown as mean ± S.D. of 6 wt and 5 ko mice. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
|
|
Tissue LPL Activities and LPL mRNA
Levels--
Because the decreased availability of plasma NEFA and
VLDL-TG might cause a shortage of NEFA supply in cardiac and skeletal muscle, we considered whether LPL might be induced in these tissues to
provide them with additional energy substrate. LPL activities were
measured in muscle and AT. As shown in Fig.
6, HSL deficiency led to a highly
significant 80, 76, and 48% increase of the LPL activity in cardiac
muscle, skeletal muscle, and WAT, respectively, when a group of eight
fasted animals was analyzed (Fig. 6A). In BAT, LPL activity
was decreased by 73%. In the fed state (Fig. 6B), the
increase of LPL activities in cardiac muscle (32%) and skeletal muscle
(22%) was less pronounced than in fasted animals. In the WAT and BAT
of fed HSL-ko mice, LPL activities were reduced by 56 and 71%,
respectively. Northern blot experiments were performed to analyze
whether the changes in LPL activities are caused by alterations in LPL
mRNA levels. In WAT, BAT, and cardiac muscle of fasted HSL-ko
animals and controls, LPL mRNA levels were essentially identical in
all tissues despite the marked variation in LPL activities observed in
HSL-ko mice compared with controls (Fig.
7). These results, which were confirmed
in multiple analyses, suggested that the compensatory up-regulation of
LPL activity in cardiac and skeletal muscle might contribute to the low
plasma TG levels observed in HSL-ko mice.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 6.
Tissue LPL activities in the fasted
(A) and fed state (B). Tissue
specimens were surgically removed from mice in the mornings after they
had normal access to food (fed samples) and after a fasting period of
16 h. The epididymal fat pads, brown adipose tissue, and cardiac
and skeletal muscle specimens were incubated in 1 ml of Dulbecco's
modified Eagle's medium with 2% bovine serum albumin and 2 units/ml
heparin for 1 h at 37 °C. The LPL activity in the supernatants
was assayed in duplicate. Values represent means ± S.D.
of tissue samples from 8 mice of each genotype. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
|
|

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 7.
LPL mRNA levels in WAT, BAT, and cardiac
muscle of fasted mice. Northern blotting analysis was performed
with RNA tissue samples from WAT, BAT, and cardiac muscle
(CM). Total RNA (10 µg) was subjected to
formaldehyde/agarose gel electrophoresis and blotted onto a nylon
membrane. After hybridization of the blot with a
32P-labeled mouse LPL mRNA-specific probe,
signals were visualized by exposure to a phosphorimaging screen. The
size of LPL mRNA is indicated. For comparison of RNA quantities,
the gel was stained with ethidium bromide and photographed before
blotting.
|
|
Decreased Levels of Neutral Lipids in Cardiac Muscle
ofHSL-ko Mice--
The decreased ACR and the low substrate
availability suggested that HSL-ko mice are insufficiently supplied
with NEFA. Therefore, the storage pool of neutral lipids in cardiac
muscle was determined by measuring the tissue-associated TG levels of
animals in the fed and fasted state. As shown in Fig.
8 the TG content was decreased by 45% in
the fed and 70% in the fasted state in the hearts of HSL-ko mice
compared with controls.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 8.
Cardiac muscle TG contents from mice in the
fed state and from mice after a 16-h fasting period. Before
surgical removal of the hearts, mice were perfused with 0.9% NaCl to
remove any blood lipids. Tissues were homogenized, and tissue lipids
were extracted by the method of Folch (27). TG contents were
determined enzymatically. Values represent means ± S.D. *,
p < 0.05; **, p < 0.01.
|
|
 |
DISCUSSION |
The physiological importance of HSL for the metabolism of
AT-associated fat stores is evident from recent studies in
HSL-deficient mice (23, 24, 35, 36). In the absence of HSL, the
hydrolysis of TG and diglycerides is impaired, leading to a pronounced
decrease of plasma NEFA concentrations especially in fasted animals
(23). In the present study we show that decreased plasma NEFA
concentrations cause marked alterations in the plasma lipoprotein
pattern with decreased plasma TG levels and increased total and HDL
cholesterol concentrations. In the liver, HSL-ko mice exhibited
decreased VLDL synthesis, decreased TG storage droplets, and decreased ketogenesis.
Generally, NEFA that enter hepatocytes are subsequently processed by
one of two possible pathways. First, re-esterification of NEFA at the
endoplasmic reticulum leads to the formation of cytoplasmic lipid
storage droplets. Second, mitochondrial import feeds into -oxidation
or ketogenesis. According to current models, lipid storage droplets
represent the major pool of fatty acids for subsequent VLDL production
(37). Following TG hydrolysis by a currently unidentified TG hydrolase
and re-esterification at the endoplasmic reticulum (38), TG are
incorporated into VLDL by a process that involves microsomal lipid
transfer protein (MTP) (39). Our data are consistent with this model
and show that in a condition of decreased plasma NEFA level, as
observed in fasted HSL-ko mice, both cytoplasmic fat stores and VLDL
synthesis are decreased. It is interesting to note that additional
potential sources of fatty acids to fuel lipid droplet and VLDL
production, such as hepatic de novo fatty acid synthesis
and/or remnant particle uptake from the vascular system, cannot
entirely compensate for the deficiency of fatty acid transport from AT
to the liver.
Considering the second possible fate of NEFA that enter hepatocytes,
namely mitochondrial import for -oxidation or ketogenesis, it was
interesting to observe a pronounced decrease in the ketone body
concentration in plasma suggesting that this second pathway of fatty
acid processing is also less efficient when HSL-mediated production of
NEFA from fat stores is absent. Alternatively, increased ketone body
utilization by peripheral tissues might also contribute to the drastic
decrease in ketone body concentration in plasma of fasted animals. In
view of the importance of ketone bodies as an energy substrate,
particularly in the brain, low rates of hepatic ketone body production
in HSL-ko mice might cause a serious problem during prolonged fasting
in HSL-deficient animals.
Decreased hepatic VLDL production as a result of the defective TG
lipolysis in AT of HSL-ko mice was also associated with alterations in
the catabolic pathways of VLDL. VLDL turnover experiments revealed
significantly increased FCR values in HSL-ko mice compared with
controls. The increased FCR is explained mainly by the much smaller TG
pool size in HSL-deficient animals. In fact, when the ACR was
calculated as a product of the FCR × pool size, a decreased ACR
was found in HSL-deficient mice. Because in steady state conditions the
ACR is a measure of the production rate, this result confirms our
observations of decreased VLDL synthesis in Triton WR-1339 experiments.
The decreased TG pool in fasted HSL-ko animals was not only a result of
decreased VLDL production but was also caused by the induction of LPL
activities in cardiac and skeletal muscle. The statistically highly
significant increase of LPL activities in muscle might reflect an
effort to increase the uptake of energy substrate in a situation of
extremely low plasma concentrations of NEFA and TG-rich lipoproteins.
The regulation of LPL in AT was found to be less uniform. Independent
of the feeding/fasting state LPL was markedly reduced in BAT of HSL-ko
mice. In WAT, LPL was induced in fasted mice but reduced in fed
HSL-deficient mice compared with control mice. Increased LPL activity
in the muscle and WAT of fasted mice is expected to effectively lower plasma TG in addition to the decreased VLDL synthesis in HSL-ko mice,
because the tissue-specific LPL activity in cardiac muscle has been
shown to be particularly powerful in the catabolism of TG-rich
lipoproteins (40). Although LPL activity in BAT is decreased, the total
tissue LPL activity is essentially unchanged because the tissue mass is
increased in HSL-deficient mice (23, 35). Taken together, it is
reasonable to assume that the total LPL-mediated lipolytic activity of
the body is determined by the tissue-specific activities in cardiac
muscle, skeletal muscle, and WAT, which are all increased in fasted
HSL-ko mice.
The molecular mechanisms responsible for the coordinate regulation of
LPL in the presence or absence of HSL remain to be elucidated. In human
AT, such a coordinated regulation of LPL and HSL was observed,
suggesting a control mechanism of fat storage and mobilization (41). A
coordinate regulation of the enzymes across tissue boundaries, however,
has not been reported. Induction of LPL activity in muscle and WAT and
reduction of LPL in BAT is a post-transcriptional process, because LPL
mRNA levels were identical in these tissues in HSL-ko and control
mice. Apparently, variations in LPL activities are a result of changes
in enzyme processing or enzyme translocation to its final destination,
the heparan sulfate anchors in the capillary endothelium.
Post-transcriptional regulation of LPL has been observed in previous
studies in response to hormones and cytokines such as insulin and
interleukin-1 (42, 43). The signals that trigger the
post-transcriptional induction of LPL in HSL-deficient mice are
presently unknown. However, several scenarios are conceivable. First,
the lack of induction of LPL in WAT of HSL-ko mice in response to
feeding indicates a defect in insulin action, because it is well
documented that the postprandial up-regulation of WAT LPL is mediated
by insulin. Second, the intracellular lipid stores in peripheral
tissues, particularly the heart, might act as a "lipostat"
signaling the increased requirement for fatty acids upon depletion. A
similar function has been proposed for lipid stores in pancreatic
-cells (36, 44). Third, the decreased availability of fatty acids or
a subclass thereof (e.g. essential fatty acids) from plasma
or changes in the hormonal status because of HSL deficiency might
induce the post-transcriptional processing of LPL. The lipostat
hypothesis is also consistent with our observation that, in contrast to
all other peripheral tissues, LPL is drastically down-regulated in BAT
of HSL-deficient mice. We assume that increased BAT mass and BAT lipid
content as observed in HSL-ko mice (23) inhibit LPL expression at the
post-transcriptional level.
The induction of LPL was highest in cardiac muscle, in accordance with
the current concept that the heart is particularly dependent on NEFA
uptake as oxidative fuel. However, despite this induction, the steady
state concentration of cardiac muscle TG stores were decreased in
HSL-ko mice. The normal heart also exhibits the capacity to store
limited amounts of fatty acids as TG droplets (45). This myocardial TG
content is kept relatively constant under physiological conditions,
suggesting a strictly regulated equilibrium between oxidative fatty
acid consumption and fatty acid uptake. In fasted HSL-ko mice, the
cardiac TG pool was markedly reduced, indicating an imbalance of fatty
acid uptake versus consumption, which was not compensated by
the up-regulation of the tissue specific LPL activity.
Decreased plasma TG levels as a result of decreased hepatic VLDL
synthesis and increased peripheral VLDL catabolism are associated with
increased plasma cholesterol and HDL cholesterol concentrations. These
data are in agreement with the well established concept that increased
catabolism of TG-rich lipoproteins due to the induction of LPL is an
important determinant of HDL cholesterol levels. It is generally
accepted that the LPL-mediated lipolysis of chylomicrons and VLDL
provides "surface remnants" as precursor particles that together
with hepatic pre 1-LpA-I particles are converted to mature -LpA-I
particles by the action of ABC-A1, lipid transfer proteins, and
lecithin:cholesterol acyl transferase (46-53). It is reasonable to
assume that the increased LPL activities found in muscle and WAT at
least partially account for the observed increase in HDL cholesterol levels.
In summary, we conclude that the phenotypic changes observed in
HSL-deficient mice indicate an important function for the enzyme in the
regulation of lipid homeostasis and lipoprotein metabolism.
 |
FOOTNOTES |
*
This work was supported by Grants SFB-F007,
SFB-F701, SFB-F713, and P14309 of the "Austrian Fonds zur
Förderung der Wissenschaftlichen Forschung" and by the BIOMED-2
program, PL-963324, from the European Union.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Institute of
Molecular Biology, Biochemistry and Microbiology, University of Graz, Heinrichstr. 31a, Graz A-8010, Austria. Tel.: +43-316-380-1900; Fax: +43-316-380-9016; E-mail: rudolf.zechner@kfunigraz.ac.at.
Published, JBC Papers in Press, January 23, 2002, DOI 10.1074/jbc.M108640200
 |
ABBREVIATIONS |
The abbreviations used are:
WAT, white adipose
tissue;
HSL, hormone-sensitive lipase;
TG, triglycerides;
AT, adipose
tissue;
BAT, brown adipose tissue;
NEFA, non-esterified fatty acids;
ko, knock-out;
wt, wild type;
LPL, lipoprotein lipase;
TC, total
cholesterol;
HDL, high density lipoprotein;
VLDL, very low density
lipoprotein;
FCR, fractional catabolic rate;
ACR, absolute catabolic
rate;
PL, phospholipid;
FPLC, fast protein liquid chromatography;
wt, wild type.
 |
REFERENCES |
| 1.
|
Sztalryd, C.,
and Kraemer, F. B.
(1994)
Am. J. Physiol.
266,
179-185
|
| 2.
|
Langfort, J.,
Ploug, T.,
Ihlemann, J.,
Enevoldsen, L. H.,
Stallknecht, B.,
Saldo, M.,
Kjaer, M.,
Holm, C.,
and Galbo, H.
(1998)
Adv. Exp. Med. Biol.
441,
219-228
|
| 3.
|
Bulow, J.,
Simonsen, L.,
Wiggins, D.,
Humphreys, S. M.,
Frayn, K. N.,
Powell, D.,
and Gibbons, G. F.
(1999)
J. Lipid Res.
40,
2034-2043
|
| 4.
|
Gibbons, G. F.,
Islam, K.,
and Pease, R. J.
(2000)
Biochim. Biophys. Acta
1483,
37-57
|
| 5.
|
Goldberg, I.
(1996)
Curr. Opin. Lipidol.
7,
184-192
|
| 6.
|
Olivecrona, T.,
and Bengtsson-Olivecrona, G.
(1987)
in
Lipoprotein Lipase
(Borensztajn, J., ed)
, pp. 15-25, Evener, Chicago
|
| 7.
|
Belfrage, P.,
Jergil, B.,
Stralfors, P.,
and Tornqvist, H.
(1977)
FEBS Lett.
75,
259-264
|
| 8.
|
Yeaman, S. J.
(1990)
Biochim. Biophys. Acta
1052,
128-132
|
| 9.
|
Khoo, J. C.,
Reue, K.,
Steinberg, D.,
and Schotz, M. C.
(1993)
J. Lipid Res.
34,
1969-1974
|
| 10.
|
Wei, S.,
Lai, K.,
Patel, S.,
Piantedosi, R.,
Shen, H.,
Colantuoni, V.,
Kraemer, F. B.,
and Blaner, W. S.
(1997)
J. Biol. Chem.
272,
14159-14165
|
| 11.
|
Contreras, J. A.,
Holm, C.,
Martin, A.,
Gaspar, M. L.,
and Lasuncion, M. A.
(1994)
Isr. J. Med. Sci.
30,
778-781
|
| 12.
|
Holm, C.,
Belfrage, P.,
and Fredrikson, G.
(1987)
Biochem. Biophys. Res. Commun.
148,
99-105
|
| 13.
|
Mulder, H.,
Holst, L. S.,
Svensson, H.,
Degerman, E.,
Sundler, F.,
Ahren, B.,
Rorsman, P.,
and Holm, C.
(1999)
Diabetes
48,
228-232
|
| 14.
|
Frayn, K. N.,
Shadid, S.,
Hamlani, R.,
Humphreys, S. M.,
Clark, M. L.,
Fielding, B. A.,
Boland, O.,
and Coppack, S. W.
(1994)
Am. J. Physiol.
266,
308-317
|
| 15.
|
Frayn, K. N,
Humphreys, S. M.,
and Coppack, S. W
(1995)
Proc. Nutr. Soc.
54,
177-189
|
| 16.
|
Yip, R. G.,
and Goodman, H. M.
(1999)
Endocrinology
140,
1219-1227
|
| 17.
|
Elks, M. L.,
and Manganiello, V. C.
(1985)
Endocrinology
116,
2119-2121
|
| 18.
|
Goldberg, D. I.,
and Khoo, J. C.
(1985)
J. Biol. Chem.
260,
5879-5882
|
| 19.
|
Oscai, L. B.,
Caruso, R. A.,
Wergeles, A. C.,
and Palmer, W. K.
(1981)
J. Appl. Physiol.
50,
250-254
|
| 20.
|
Shepherd, R. E.,
Noble, E. G.,
Klug, G. A.,
and Gollnick, P. D.
(1981)
J. Appl. Physiol.
50,
143-148
|
| 21.
|
McKnight, G. S.,
Cummings, D. E.,
Amieux, P. S.,
Sikorski, M. A.,
Brandon, E. P.,
Planas, J. V.,
Motamed, K.,
and Idzerda, R. L.
(1998)
Recent Prog. Horm. Res.
53,
139-159
|
| 22.
|
Syu, L. J.,
and Saltiel, A. R.
(1999)
Mol. Cell
4,
109-115
|
| 23.
|
Osuga, J.,
Ishibashi, S.,
Oka, T.,
Yagyu, H.,
Tozawa, R.,
Fujimoto, A.,
Shionoiri, F.,
Yahagi, N.,
Kraemer, F. B.,
Tsutsumi, O.,
and Yamada, N.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
787-792
|
| 24.
|
Haemmerle, G.,
Zimmermann, R.,
Hayn, M.,
Theussl, C.,
Waeg, G.,
Wagner, E.,
Sattler, W.,
Magin, T. M.,
Wagner, E. F.,
and Zechner, R.
(2002)
J. Biol. Chem.
277,
4806-4815
|
| 25.
|
Raclot, T.,
Dauzats, M.,
and Langin, D.
(1998)
Biochem. Biophys. Res. Commun.
245,
510-513
|
| 26.
|
Romeis, B.
(1989)
in
Mikroskopische Technik
(Ruzicka, F., ed), 17th Ed.
, pp. 378-382, Urban and Schwarzenberg, Munich
|
| 27.
|
Folch, J.,
Lees, M.,
and Sloane-Stanley, G. H.
(1957)
J. Biol. Chem.
226,
497-509
|
| 28.
|
Aalto-Setala, K.,
Fisher, E. A,
Chen, X.,
Chajek-Shaul, T.,
Hayek, T.,
Zechner, R.,
Walsh, A.,
Ramakrishnan, R.,
Ginsberg, H. N.,
and Breslow, J. L.
(1992)
J. Clin. Invest.
90,
1889-1900
|
| 29.
|
Kuipers, F.,
Jong, M. C,
Lin, Y.,
Eck, M.,
Havinga, R.,
Bloks, V.,
Verkade, H. J,
Hofker, M. H,
Moshage, H.,
Berkel, T. J,
Vonk, R. J.,
and Havekes, L. M.
(1997)
J. Clin. Invest.
100,
2915-2922
|
| 30.
| Mathews, C. H. Phys. Med. Biol. 2, 36-43
|
| 31.
|
Gaw, A.,
Packard, C. J.,
and Shepherd, J.
(1992)
in
Lipoprotein Analysis, A Practical Approach
(Converse, C. A.
, and Skinner, E. R., eds)
, pp. 139-140, Oxford University Press, Oxford
|
| 32.
|
Levak-Frank, S.,
Radner, H.,
Walsh, A.,
Stollberger, R.,
Knipping, G.,
Hoefler, G.,
Sattler, W.,
Weinstock, P. H,
Breslow, J. L.,
and Zechner, R.
(1995)
J. Clin. Invest.
96,
976-986
|
| 33.
|
Kratky, D.,
Strauss, J. G.,
and Zechner, R.
(2001)
Biochem. J.
355,
647-652
|
| 34.
|
Weinstock, P. H,
Bisgaier, C. L,
Aalto Setala, K.,
Radner, H.,
Ramakrishnan, R.,
Levak Frank, S.,
Essenburg, A. D,
Zechner, R.,
and Breslow, J. L
(1995)
J. Clin. Invest.
96,
2555-2568
|
| 35.
|
Wang, S. P,
Laurin, N.,
Himms-Hagen, J.,
Rudnicki, M. A,
Levy, E.,
Robert, M. F,
Pan, L.,
Oligny, L.,
and Mitchell, G. A.
(2001)
Obes. Res.
9,
119-128
|
| 36.
|
Roduit, R.,
Masiello, P.,
Wang, S. P., Li, H.,
Mitchell, G. A.,
and Prentki, M.
(2001)
Diabetes
50,
1970-1975
|
| 37.
|
Lewis, G. F.
(1997)
Curr. Opin. Lipidol.
8,
146-153
|
| 38.
|
Speake, B. K,
Murray, A. M.,
and Noble, R. C.
(1998)
Prog. Lipid. Res.
37,
1-32
|
| 39.
|
Gordon, D. A.
(1997)
Curr. Opin. Lipidol.
8,
131-137
|
| 40.
|
Levak-Frank, S.,
Hofmann, W.,
Weinstock, P. H.,
Radner, H.,
Sattler, W.,
Breslow, J. L.,
and Zechner, R.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
3165-3170
|
| 41.
|
Frayn, K. N.,
Coppack, S. W.,
Fielding, B. A.,
and Humphreys, S. M.
(1995)
Adv. Enzyme Regul.
35,
163-178
|
| 42.
|
Ewart, H. S.,
and Severson, D. L.
(1999)
Biochem. J.
340,
485-490
|
| 43.
|
Enerback, S.,
and Gimble, J. M.
(1993)
Biochim. Biophys. Acta
1169,
107-125
|
| 44.
|
Winzell, M. S.,
Svensson, H.,
Arner, P.,
Ahren, B.,
and Holm, C.
(2001)
Diabetes
50,
2225-2230
|
| 45.
|
Saddik, M.,
and Lopaschuk, G. D.
(1991)
J. Biol. Chem.
266,
8162-8170
|
| 46.
|
Barrans, A.,
Jaspard, B.,
Barbaras, R.,
Chap, H.,
Perret, B.,
and Collet, X.
(1996)
Biochim. Biophys. Acta
1300,
73-85
|
| 47.
|
Clay, M. A,
Pyle, D. H,
Rye, K. A.,
and Barter, P. J.
(2000)
J. Biol. Chem.
275,
9019-9025
|
| 48.
|
Rye, K. A,
Clay, M. A.,
and Barter, P. J.
(1999)
Atherosclerosis
145,
227-238
|
| 49.
|
Oram, J. F,
and Vaughan, A. M.
(2000)
Curr. Opin. Lipidol.
11,
253-260
|
| 50.
|
Brooks-Wilson, A.,
Marcil, M.,
Clee, S. M,
Zhang, L. H,
Roomp, K.,
van Dam, M., Yu, L.,
Brewer, C.,
Collins, J. A,
Molhuizen, H. O,
Loubser, O.,
Ouelette, B. F,
Fichter, K.,
Ashbourne-Excoffon, K. J,
Sensen, C. W,
Scherer, S.,
Mott, S.,
Denis, M.,
Martindale, D.,
Frohlich, J.,
Morgan, K.,
Koop, B.,
Pimstone, S.,
Kastelein, J. J.,
and Hayden, M. R.
(1999)
Nat. Genet.
22,
336-345
|
| 51.
|
Bodzioch, M.,
Orso, E.,
Klucken, J.,
Langmann, T.,
Bottcher, A.,
Diederich, W.,
Drobnik, W.,
Barlage, S.,
Buchler, C.,
Porsch Ozcurumez, M.,
Kaminski, W. E,
Hahmann, H. W,
Oette, K.,
Rothe, G.,
Aslanidis, C.,
Lackner, K. J.,
and Schmitz, G.
(1999)
Nat. Genet.
22,
347-351
|
| 52.
|
Rust, S.,
Rosier, M.,
Funke, H.,
Real, J.,
Amoura, Z.,
Piette, J. C,
Deleuze, J. F,
Brewer, H. B,
Duverger, N.,
Denefle, P.,
and Assmann, G.
(1999)
Nat. Genet.
22,
352-355
|
| 53.
|
Santamarina-Fojo, S.,
Lambert, G.,
Hoeg, J. M,
and Brewer, H. B.
(2000)
Curr. Opin. Lipidol.
11,
267-275
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Zechner, P. C. Kienesberger, G. Haemmerle, R. Zimmermann, and A. Lass
Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores
J. Lipid Res.,
January 1, 2009;
50(1):
3 - 21.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Fernandez, M. Lindholm, M. Krogh, S. Lucas, S. Larsson, P. Osmark, K. Berger, J. Boren, B. Fielding, K. Frayn, et al.
Disturbed cholesterol homeostasis in hormone-sensitive lipase-null mice
Am J Physiol Endocrinol Metab,
October 1, 2008;
295(4):
E820 - E831.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Sekiya, J.-i. Osuga, N. Yahagi, H. Okazaki, Y. Tamura, M. Igarashi, S. Takase, K. Harada, S. Okazaki, Y. Iizuka, et al.
Hormone-sensitive lipase is involved in hepatic cholesteryl ester hydrolysis
J. Lipid Res.,
August 1, 2008;
49(8):
1829 - 1838.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Fernandez, O. Hansson, P. Nevsten, C. Holm, and C. Klint
Hormone-sensitive lipase is necessary for normal mobilization of lipids during submaximal exercise
Am J Physiol Endocrinol Metab,
July 1, 2008;
295(1):
E179 - E186.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Bartness and C. K. Song
Thematic review series: Adipocyte Biology. Sympathetic and sensory innervation of white adipose tissue
J. Lipid Res.,
August 1, 2007;
48(8):
1655 - 1672.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Magnusson-Olsson, S. Lager, B. Jacobsson, T. Jansson, and T. L. Powell
Effect of maternal triglycerides and free fatty acids on placental LPL in cultured primary trophoblast cells and in a case of maternal LPL deficiency
Am J Physiol Endocrinol Metab,
July 1, 2007;
293(1):
E24 - E30.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. E. Jocken, D. Langin, E. Smit, W. H. M. Saris, C. Valle, G. B. Hul, C. Holm, P. Arner, and E. E. Blaak
Adipose Triglyceride Lipase and Hormone-Sensitive Lipase Protein Expression Is Decreased in the Obese Insulin-Resistant State
J. Clin. Endocrinol. Metab.,
June 1, 2007;
92(6):
2292 - 2299.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Miyoshi, J. W. Perfield II, S. C. Souza, W.-J. Shen, H.-H. Zhang, Z. S. Stancheva, F. B. Kraemer, M. S. Obin, and A. S. Greenberg
Control of Adipose Triglyceride Lipase Action by Serine 517 of Perilipin A Globally Regulates Protein Kinase A-stimulated Lipolysis in Adipocytes
J. Biol. Chem.,
January 12, 2007;
282(2):
996 - 1002.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schweiger, R. Schreiber, G. Haemmerle, A. Lass, C. Fledelius, P. Jacobsen, H. Tornqvist, R. Zechner, and R. Zimmermann
Adipose Triglyceride Lipase and Hormone-sensitive Lipase Are the Major Enzymes in Adipose Tissue Triacylglycerol Catabolism
J. Biol. Chem.,
December 29, 2006;
281(52):
40236 - 40241.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Yvan-Charvet, P. Even, N. Lamande, P. Ferre, and A. Quignard-Boulange
Prevention of Adipose Tissue Depletion during Food Deprivation in Angiotensin Type 2 Receptor-Deficient Mice
Endocrinology,
November 1, 2006;
147(11):
5078 - 5086.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Haemmerle, A. Lass, R. Zimmermann, G. Gorkiewicz, C. Meyer, J. Rozman, G. Heldmaier, R. Maier, C. Theussl, S. Eder, et al.
Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase.
Science,
May 5, 2006;
312(5774):
734 - 737.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Loffler, M. Bilban, M. Reimers, W. Waldhausl, and T. M. Stulnig
Blood Glucose-Lowering Nuclear Receptor Agonists Only Partially Normalize Hepatic Gene Expression in db/db Mice
J. Pharmacol. Exp. Ther.,
February 1, 2006;
316(2):
797 - 804.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. W. Zderic and M. T. Hamilton
Physical inactivity amplifies the sensitivity of skeletal muscle to the lipid-induced downregulation of lipoprotein lipase activity
J Appl Physiol,
January 1, 2006;
100(1):
249 - 257.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Hansson, M. Donsmark, C. Ling, P. Nevsten, M. Danfelter, J. L. Andersen, H. Galbo, and C. Holm
Transcriptome and proteome analysis of soleus muscle of hormone-sensitive lipase-null mice
J. Lipid Res.,
December 1, 2005;
46(12):
2614 - 2623.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Langin, A. Dicker, G. Tavernier, J. Hoffstedt, A. Mairal, M. Ryden, E. Arner, A. Sicard, C. M. Jenkins, N. Viguerie, et al.
Adipocyte Lipases and Defect of Lipolysis in Human Obesity
Diabetes,
November 1, 2005;
54(11):
3190 - 3197.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Fortier, K. Soni, N. Laurin, S. P. Wang, P. Mauriege, F. R. Jirik, and G. A. Mitchell
Human hormone-sensitive lipase (HSL): expression in white fat corrects the white adipose phenotype of HSL-deficient mice
J. Lipid Res.,
September 1, 2005;
46(9):
1860 - 1867.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-Y. Park, H.-J. Kim, S. Wang, T. Higashimori, J. Dong, Y.-J. Kim, G. Cline, H. Li, M. Prentki, G. I. Shulman, et al.
Hormone-sensitive lipase knockout mice have increased hepatic insulin sensitivity and are protected from short-term diet-induced insulin resistance in skeletal muscle and heart
Am J Physiol Endocrinol Metab,
July 1, 2005;
289(1):
E30 - E39.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Duivenvoorden, B. Teusink, P. C. Rensen, J. A. Romijn, L. M. Havekes, and P. J. Voshol
Apolipoprotein C3 Deficiency Results in Diet-Induced Obesity and Aggravated Insulin Resistance in Mice
Diabetes,
March 1, 2005;
54(3):
664 - 671.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Wang and B. Paigen
Genetics of Variation in HDL Cholesterol in Humans and Mice
Circ. Res.,
January 7, 2005;
96(1):
27 - 42.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. W. Cohen, R. Hnasko, W. Schubert, and M. P. Lisanti
Role of Caveolae and Caveolins in Health and Disease
Physiol Rev,
October 1, 2004;
84(4):
1341 - 1379.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Fortier, S. P. Wang, P. Mauriege, M. Semache, L. Mfuma, H. Li, E. Levy, D. Richard, and G. A. Mitchell
Hormone-sensitive lipase-independent adipocyte lipolysis during {beta}-adrenergic stimulation, fasting, and dietary fat loading
Am J Physiol Endocrinol Metab,
August 1, 2004;
287(2):
E282 - E288.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yamaguchi, N. Omatsu, S. Matsushita, and T. Osumi
CGI-58 Interacts with Perilipin and Is Localized to Lipid Droplets: POSSIBLE INVOLVEMENT OF CGI-58 MISLOCALIZATION IN CHANARIN-DORFMAN SYNDROME
J. Biol. Chem.,
July 16, 2004;
279(29):
30490 - 30497.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-L. Peyot, C. J. Nolan, K. Soni, E. Joly, R. Lussier, B. E. Corkey, S. P. Wang, G. A. Mitchell, and M. Prentki
Hormone-Sensitive Lipase Has a Role in Lipid Signaling for Insulin Secretion but Is Nonessential for the Incretin Action of Glucagon-Like Peptide 1
Diabetes,
July 1, 2004;
53(7):
1733 - 1742.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Sekiya, J.-i. Osuga, H. Okazaki, N. Yahagi, K. Harada, W.-J. Shen, Y. Tamura, S. Tomita, Y. Iizuka, K. Ohashi, et al.
Absence of Hormone-sensitive Lipase Inhibits Obesity and Adipogenesis in Lepob/ob Mice
J. Biol. Chem.,
April 9, 2004;
279(15):
15084 - 15090.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Harada, W.-J. Shen, S. Patel, V. Natu, J. Wang, J.-i. Osuga, S. Ishibashi, and F. B. Kraemer
Resistance to high-fat diet-induced obesity and altered expression of adipose-specific genes in HSL-deficient mice
Am J Physiol Endocrinol Metab,
December 1, 2003;
285(6):
E1182 - E1195.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Zimmermann, G. Haemmerle, E. M. Wagner, J. G. Strauss, D. Kratky, and R. Zechner
Decreased fatty acid esterification compensates for the reduced lipolytic activity in hormone-sensitive lipase-deficient white adipose tissue
J. Lipid Res.,
November 1, 2003;
44(11):
2089 - 2099.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Mulder, M. Sorhede-Winzell, J. A. Contreras, M. Fex, K. Strom, T. Ploug, H. Galbo, P. Arner, C. Lundberg, F. Sundler, et al.
Hormone-sensitive Lipase Null Mice Exhibit Signs of Impaired Insulin Sensitivity whereas Insulin Secretion Is Intact
J. Biol. Chem.,
September 19, 2003;
278(38):
36380 - 36388.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Voshol, G. Haemmerle, D. M. Ouwens, R. Zimmermann, R. Zechner, B. Teusink, J. A. Maassen, L. M. Havekes, and J. A. Romijn
Increased Hepatic Insulin Sensitivity Together with Decreased Hepatic Triglyceride Stores in Hormone-Sensitive Lipase-Deficient Mice
Endocrinology,
August 1, 2003;
144(8):
3456 - 3462.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X.-Y. Wen, R. A. Hegele, J. Wang, D. Y. Wang, J. Cheung, M. Wilson, M. Yahyapour, Y. Bai, L. Zhuang, J. Skaug, et al.
Identification of a novel lipase gene mutated in lpd mice with hypertriglyceridemia and associated with dyslipidemia in humans
Hum. Mol. Genet.,
May 15, 2003;
12(10):
1131 - 1143.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Misso, Y. Murata, W. C. Boon, M. E. E. Jones, K. L. Britt, and E. R. Simpson
Cellular and Molecular Characterization of the Adipose Phenotype of the Aromatase-Deficient Mouse
Endocrinology,
April 1, 2003;
144(4):
1474 - 1480.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. B. Kraemer and W.-J. Shen
Hormone-sensitive lipase: control of intracellular tri-(di-)acylglycerol and cholesteryl ester hydrolysis
J. Lipid Res.,
October 1, 2002;
43(10):
1585 - 1594.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|